Searched for
CIPLA EUROPE
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- AI video startup TrueFan raises $10 million led by Baring PE, Z3PartnersGurugram's TrueFan AI secured $10 million, valuing it at $40 million, to fuel its AI-generated video platform. Serving over 100 enterprises...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Cipla Gulf expands partnership with Alvotech for commercialisation of four drugs in Australia, New ZealandCipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia a...
- Cipla inks licensing deal with Belgium's MultiG for distribution of COVID-19 antibody test kit"As part of this agreement, Cipla will be responsible for distribution of the COVID-19 rapid antibody kit that will be manufactured by Mult...
- What we had done for India, we are now doing for US: Umang Vohra, MD, CiplaIn an interview with Suman Layak, Vohra explains his strategy of taking Cipla products to global markets.
- Cipla ties up with Serum Institute to sell vaccines in South AfricaCipla said it had agreed to an exclusive deal with Serum Institute to supply vaccines to South Africa, adding a new market to their partner...
- Cipla shares end nearly 4% higher post agreement with Serum InstituteCipla's stock surged 3.23 per cent to settle at Rs 618.60 on the BSE. In intra-day, it climbed 4.13 per cent to Rs 624.
- Cipla Ltd to market Serum Institute's paediatric vaccines in EuropeCipla has launched multiple respiratory products in Europe this year, and launch of some key inhalers is expected in 2015.
- Cipla announces commercial tie-up with UK's S&D PharmaPharmaceutical firm Cipla today announced commercial collaboration with UK-based S&D Pharma in the Czech Republic and Slovakia.
- Cipla launches combination inhalers in Germany and Sweeden; stocks touch all time high, may trigger reratingThe maiden launch increases the possibility and visibility of subsequent launches of the company’s inhalers in other countries.
- Cipla, BioQuiddity ink pact to sell pain management productCipla intends to launch the CE marked OneDose ReadyfusOR pre-filled with Ropivacaine under its own label into the German market late this y...
- Ex-Teva Frank Pieters to lead Cipla's European respiratory businessCipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...
Load More
